Parameter
| Biomarker | Intestinal alkaline phosphatase (IAP) | Full name | Intestinal alkaline phosphatase | Molecular Type | Proteins (enzymes) |
|---|---|---|---|---|---|
| Molecular Formula | Human IAP: C₁₀₀₂H₁₅₄₈N₂₆₂O₂₈₄P₆Zn₂ | Molecular Weight | ~220 kDa | Core Functional Dimensions | Assessment of intestinal barrier function |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Stool/intestinal mucosal biopsy (enzyme activity assay, ELISA, immunohistochemistry) | ||
| Pathobiological Mechanisms | 1. It is expressed on the brush border of intestinal epithelium and maintains the integrity of intestinal barrier by detoxify endotoxin (LPS) and regulating the balance of intestinal flora; (2) The IAP level in the intestinal mucosa of patients with active UC is decreased (40% lower than that of healthy people), leading to increased translocation of LPS and activation of systemic inflammation; (3) The level of IAP is positively correlated with the rate of mucosal healing in UC. When IAP > 20U/mL, the rate of remission maintenance in UC patients increases by 60% | ||||
| Clinical Availability Status | Clinical Research and Application | ||||
| Notes and Dynamics | Oral IAP reduced intestinal permeability and LPS level by 50% in a mouse model of UC; (2) The phase Ⅱ clinical trial (NCT05698712) of IAP as a monitoring indicator in UC remission is ongoing, and preliminary results show that IAP can reduce the risk of recurrence | ||||